Fulcrum Therapeutics Inc. (FULC) Next Earnings Date & Expected ±3.8% Move

Per the Roarable RQD rating, FULC scores 34 out of 100 and receives a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The score is the sum of five pillars, each weighted at 20 points:

• Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -35% and an FCF yield of -20.97%. For a prospective investor, this means the business is consuming capital rather than generating it relative to the value assigned to it.
• Whale / 13F Flow: 8 / 20. The rating references institutional accumulation and options positioning. The pillar is scored modestly, and no holder-level detail is supplied in the source data to verify the direction or size of these flows.
• Insider Conviction: 3 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar, indicating weak insider signal strength.
• Macro Regime Fit: 6 / 20. The rating cites a beta of 1.0 and sector sensitivity. The stock moves in line with the broader market, offering no defensive characteristic in this framework.
• Forensic Balance Sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. This is the highest pillar but still reflects a weak forensic profile on the Piotroski measure.

Taken together, the investor implication is that upside depends on a turnaround in cash generation, which the current metrics do not yet show. Valuation tradeoffs are significant: with negative ROIC and negative FCF yield, the stock's price cannot be anchored to current earnings or cash flow, and any position is effectively a bet on future outcomes not visible in the supplied data.

Fulcrum Therapeutics Inc. (FULC) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.3B. Product, customer, and revenue-model details are not available in source data. The FY 2025 and FY 2024 financials report revenue of $0.0M in each period.

Per the SEC financials, operating and net losses are reported in every period shown, and gross, operating, and net margins are each listed as 0% in the market data. The market data reports ROIC of -35%. The Roarable rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Reported cash rose to $197.5M in FY 2025 from $58.2M in FY 2024, while debt is listed as N/A in all periods.

Per the recent news and catalysts feed, five items reference FULC, all sourced from aggregators and each carrying a YELLOW light and MARKET WIRE impact label. They include a StockInvest.us forecast piece, a Yahoo! Finance Canada seasonal returns chart, a TradingView estimates item, a Stock Titan report on a Bank of America amended passive stake filing, and a Morningstar piece on fair-deal questions across several tickers including FULC. A TradingView item also lists a Q3'26 EPS estimate of (0.07) USD. The feed contains no company-issued releases or clinical/regulatory events. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What is the company's revenue model and product pipeline, given reported revenue of $0.0M across all periods?
• What drove the FY 2025 net loss of $-74.9M against a FY 2024 net loss of $-9.7M, and what is the expected cash burn path?
• What is the basis for the reported $197.5M cash balance, and how long does it fund current operating losses?
• Why is the debt figure N/A in every period, and how does the 0.5 Debt/Equity ratio reconcile with that?
• What are the analyst consensus, price targets, and insider or 13F holdings, given that the analyst and holders sections are empty?